1-6 of 6
Yan Feng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

Martin Gutierrez, Victor Moreno, Kimberley M. Heinhuis, Anthony J. Olszanski, Anna Spreafico, Michael Ong, Quincy Chu, Richard D. Carvajal, José Trigo, Maria Ochoa de Olza, Mariano Provencio, Filip Yves De Vos, Filippo De Braud, Stephen Leong, Deanne Lathers, Rui Wang, Palani Ravindran, Yan Feng, Praveen Aanur, Ignacio Melero
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (2): 460–472.
https://doi.org/10.1158/1078-0432.CCR-20-1830
Published: 19 January 2021
View article titled, OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Open the PDF for OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

Rui Wang, Chan Gao, Megan Raymond, Gennaro Dito, Dominic Kabbabe, Xiao Shao, Ed Hilt, Yongliang Sun, Irene Pak, Martin Gutierrez, Ignacio Melero, Anna Spreafico, Richard D. Carvajal, Michael Ong, Anthony J. Olszanski, Christina Milburn, Kent Thudium, Zheng Yang, Yan Feng, Paula M. Fracasso, Alan J. Korman, Praveen Aanur, Shih-Min A. Huang, Michael Quigley
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6709–6720.
https://doi.org/10.1158/1078-0432.CCR-19-0526
Published: 15 November 2019
View article titled, An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Open the PDF for An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer

Yan Feng, Xiaoning Wang, Gaurav Bajaj, Shruti Agrawal, Akintunde Bello, Brian Lestini, Friedrich Graf Finckenstein, Jong-Soon Park, Amit Roy
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (18): 5394–5405.
https://doi.org/10.1158/1078-0432.CCR-16-2842
Published: 14 September 2017
View article titled, Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer
Open the PDF for Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer

Tuan-Jie Li, Yu-Ming Jiang, Yan-Feng Hu, Lei Huang, Jiang Yu, Li-Ying Zhao, Hai-Jun Deng, Ting-Yu Mou, Hao Liu, Yang Yang, Qi Zhang, Guo-Xin Li
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (6): 1575–1585.
https://doi.org/10.1158/1078-0432.CCR-16-0617
Published: 14 March 2017
View article titled, Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer
Open the PDF for Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (14): 3977–3986.
https://doi.org/10.1158/1078-0432.CCR-12-3243
Published: 15 July 2013
View article titled, Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
Open the PDF for Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Centromere Protein H Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival

Wen-Ting Liao, Li-Bing Song, Hui-Zhong Zhang, Xing Zhang, Ling Zhang, Wan-Li Liu, Yan Feng, Bao-Hong Guo, Hai-Qiang Mai, Su-Mei Cao, Man-Zhi Li, Hai-De Qin, Yi-Xin Zeng, Mu-Sheng Zeng
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 508–514.
https://doi.org/10.1158/1078-0432.CCR-06-1512
Published: 25 January 2007
View article titled, Centromere Protein H Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival
Open the PDF for Centromere Protein H Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival in another window